Figure e-1: MRI course of the presented case

Panel of axial MRI measurements outlining extensive increase in FLAIR hyperintense lesions. MRI images at baseline (A), 10 days (B) and 40 days (C) after two courses of pembrolizumab. (D) Time course of PML diagnosis, assessment of cellular immune status, pembrolizumab treatment, and magnetic resonance imaging. Red arrows indicate time points of pembrolizumab administration (P1, P2), T1 and T2 indicate time points of blood collection (T1, T2).

